Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19447708 | 0.88 | MAPT (0.34) | NPSR1MAPTTSHRCYP4F2CYP4A11 | |
| SCHEMBL371813 | 0.88 | MAPT (0.37) | NPSR1MAPTTSHRCYP4F2CYP4A11 | |
| SCHEMBL4398594 | 0.88 | MAPT (0.37) | NPSR1MAPTTSHRCYP4F2CYP4A11 | |
| SCHEMBL16865201 | 0.87 | MAPT (0.35) | NPSR1MAPTTSHRCYP4F2CYP4A11 | |
| SCHEMBL30706623 | 0.83 | MAPT (0.32) | NPSR1MAPT | |
| SCHEMBL13757818 | 0.80 | — | — | |
| SCHEMBL3372994 | 0.80 | — | — | |
| SCHEMBL16865155 | 0.78 | CYP17A1 (0.46) | NPSR1MAPTTSHRALDH1A1KMT2A | |
| SCHEMBL29618225 | 0.78 | MAPT (0.37) | NPSR1MAPTTSHRCYP4F2CYP4A11 | |
| Hydrochloric Acid SCHEMBL32674344 | 0.78 | GRM6 (0.33) | NPSR1TSHRALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4540255-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119677749-A | Azaquinazoline pan KRAS inhibitors | 米拉蒂治疗股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| WO-2023244615-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| EP-3694331-B1 | INDAZOLYL-SPIRO[2.3]HEXANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2022-11-16 | — | — | EP | disclosed |
| US-11174248-B2 | Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20210188818-A1 | INDAZOLYL-SPIRO[2.3]HEXANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | US | disclosed |
| EP-3694331-A1 | INDAZOLYL-SPIRO[2.3]HEXANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme Corp. (US) | 2020-08-19 | — | — | EP | disclosed |
| US-10450291-B2 | Method for producing fluorine-containing cyclopropane carboxylic acid compound | CENTRAL GLASS COMPANY, LIMITED (JP) | 2019-10-22 | — | — | US | disclosed |
| WO-2019074810-A1 | INDAZOLYL-SPIRO[2.3]HEXANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2019-04-18 | — | — | WO | disclosed |
| US-20180186763-A1 | Method for Producing Fluorine-Containing Cyclopropane Carboxylic Acid Compound | CENTRAL GLASS COMPANY, LIMITED (JP) | 2018-07-05 | — | — | US | disclosed |
| US-5510509-A | CYCLIZATION DI-LOWER ALKYL MALONATE WITH 1,2-DICHLOROALKANE, POTASSIUM CARBONATE, DEHYDRATION BY AZEOTROPICAL DISTILLATION | HULS AKTIENGESELLSCHAFT (DE) | 1996-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186763-A1 | Method for Producing Fluorine-Containing Cyclopropane Carboxylic Acid Compound | PFAS, FDPS, FIBP | NPSR1 2205/4885MAPT 1926/4885TSHR 1005/4885 |
| US-11174248-B2 | Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | LRRK2, BRSK2, CLK2 | NPSR1 4237/4885MAPT 493/4885TSHR 3909/4885 |
| US-10450291-B2 | Method for producing fluorine-containing cyclopropane carboxylic acid compound | PFAS, FDPS, FIBP | NPSR1 2205/4885MAPT 1926/4885TSHR 1005/4885 |
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | NPSR1 4157/4885MAPT 4878/4885TSHR 1916/4885 |
| US-20210188818-A1 | INDAZOLYL-SPIRO[2.3]HEXANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, BRSK2, CLK2 | NPSR1 4237/4885MAPT 493/4885TSHR 3909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.